DN 1921
Alternative Names: DantesLatest Information Update: 22 Mar 2012
Price :
$50 *
At a glance
- Originator Dendreon Corporation
- Class Monoclonal antibodies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 01 Nov 2004 This compound is still in active development
- 24 Oct 2000 New profile
- 24 Oct 2000 Preclinical development for Autoimmune disorders in USA (Unknown route)